February 2013 Editor's Picks: Products from Schenck AccuRate and Eriez - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

February 2013 Editor's Picks: Products from Schenck AccuRate and Eriez

Equipment and Processing Report


Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report

Schenck AccuRate
Bulk solids feeder is designed for low feed-rate applications

The PureFeed DP-4 feeder from Schenck AccuRate is a gravimetric feeder designed to accurately meter dry powders at low feed rates. A speed-controlled, ceramic, feed disc positioned at the base of an electropolished, stainless-steel, material-storage chamber precisely rotates and discharges material over a 20- to 2000-g feed-rate range.

Eriez
Magnetic separator grates are easy to clean

ProGrade Easy to Clean Grates in Housing, a unit available from Eriez, provides quick removal of accumulated fine iron contamination. To clean, the user unlatches the clamps on the drawer fronts and pulls the magnet bank out. The accumulated metal contamination is scraped from the tube and discharged out the front of the housing. The cleaning cycle is reduced to only a few seconds with this push-pull operation. The units are available in Rare Earth and Xtreme Rare Earth magnet strengths. Separators using the Rare Earth magnet strength are designed to remove small ferrous contaminants such as pins, staples, and clips. The Xtreme Rare Earth magnet strength can remove weakly magnetic fine ferrous contamination.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Equipment and Processing Report,
Click here